<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848237</url>
  </required_header>
  <id_info>
    <org_study_id>B-500</org_study_id>
    <nct_id>NCT00848237</nct_id>
  </id_info>
  <brief_title>HALO Patient Registry: Ablation of Barrett's Esophagus</brief_title>
  <official_title>HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It
      provides a framework for treatment and follow-up of patients with Barrett's esophagus
      (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for
      participating physician investigators to collect outcomes data related to the use of the HALO
      Ablation Systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary The HALO Patient Registry provides a framework for treatment and follow-up of
      patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is
      to provide a tool for participating physician investigators to collect outcomes data related
      to the use of the HALO Ablation Systems.

      Protocol Design:

      This is a prospective, multi-center patient Registry. Sites may choose to also
      retrospectively enroll previously treated patients (after obtaining informed consent) and
      enter retrospective data into case report forms on-line. &quot;Retrospective data collection&quot; is
      defined as any data other than patient history collected prior to signing of the informed
      consent. A set of case report forms (CRFs) is provided along with this protocol to track
      outcomes. The CRFs may be completed and retained on site, but the site is recommended to
      utilize the internet-based data entry system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up</measure>
    <time_frame>1 year</time_frame>
    <description>% of patients with 100 % resolution at 1 year follow-up. This endpoint is a visual and not reliable or accurate. A better measure of clearance of Barrett's esophagus is based on biopsies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological Clearance Rate for Intestinal Metaplasia (CE-IM)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological Clearance Rate for Dysplasia (CE-D)</measure>
    <time_frame>1 year</time_frame>
    <description>percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With Sub-squamous Intestinal Metaplasia at 1 Year Follow up</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Quality of Life Questionnaire Results: Change From Baseline to 12 Month</measure>
    <time_frame>12 month</time_frame>
    <description>Patient who completed both baseline and follow-up Quality of Life: Scores (0-10) of quality of life at baseline and 12 month follow-up were measured and changes were calculated ( 12 months minus baseline) in: concerns about the condition of esophagus, negative impact on life and esophageal cancer worry. Scale range is 0-10, 0 is min and 10 is max. Higher value represent worse outcome (such as higher concern about the condition of esophagus, negative impact on life and higher esophageal cancer worry).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Incidence</measure>
    <time_frame>12 month</time_frame>
    <description>Adverse and Serious Adverse event with Definite device relationship</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5521</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Ablation (HALO Ablation Systems)</intervention_name>
    <description>Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HALO 90</other_name>
    <other_name>HALO 360</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a candidate for ablation of Barrett's esophagus with the HALO Ablation System.

          -  Must agree to the proposed follow-up schedule and provide informed consent for
             participation.

        Exclusion Criteria:

          -  Pregnancy

          -  Prior radiation therapy to the esophagus

          -  Esophageal varices at risk for bleeding

          -  Prior Heller Myotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Shaheen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastrointestinal Associates and sites across the US</name>
      <address>
        <city>Knoxville and other US cities</city>
        <state>California</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaheen NJ, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, Corbett FS, Camara DS, Rothstein RI, Overholt BF. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. J Gastrointest Surg. 2013 Jan;17(1):21-8; discussion p.28-9. doi: 10.1007/s11605-012-2001-8. Epub 2012 Sep 11.</citation>
    <PMID>22965650</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <results_first_submitted>September 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2016</results_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Dysplasia</keyword>
  <keyword>Intestinal Metaplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5521"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4982"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="539"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5521"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Note: 6 subjects: Age unknown</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up</title>
        <description>% of patients with 100 % resolution at 1 year follow-up. This endpoint is a visual and not reliable or accurate. A better measure of clearance of Barrett's esophagus is based on biopsies.</description>
        <time_frame>1 year</time_frame>
        <population>4011 subjects provided the answers</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up</title>
          <description>% of patients with 100 % resolution at 1 year follow-up. This endpoint is a visual and not reliable or accurate. A better measure of clearance of Barrett's esophagus is based on biopsies.</description>
          <population>4011 subjects provided the answers</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4011"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histological Clearance Rate for Intestinal Metaplasia (CE-IM)</title>
        <description>Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up</description>
        <time_frame>1 year</time_frame>
        <population>4118 provided biopsies at least 1 year post RFA</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Clearance Rate for Intestinal Metaplasia (CE-IM)</title>
          <description>Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up</description>
          <population>4118 provided biopsies at least 1 year post RFA</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histological Clearance Rate for Dysplasia (CE-D)</title>
        <description>percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up</description>
        <time_frame>1 year</time_frame>
        <population>4118 provided biopsies at least 1 year post RFA and non dysplasia subjects from 4118 were removed for CE-D analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Clearance Rate for Dysplasia (CE-D)</title>
          <description>percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up</description>
          <population>4118 provided biopsies at least 1 year post RFA and non dysplasia subjects from 4118 were removed for CE-D analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Sub-squamous Intestinal Metaplasia at 1 Year Follow up</title>
        <description>Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Sub-squamous Intestinal Metaplasia at 1 Year Follow up</title>
          <description>Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface</description>
          <units>percentage of patients with SSIM</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Quality of Life Questionnaire Results: Change From Baseline to 12 Month</title>
        <description>Patient who completed both baseline and follow-up Quality of Life: Scores (0-10) of quality of life at baseline and 12 month follow-up were measured and changes were calculated ( 12 months minus baseline) in: concerns about the condition of esophagus, negative impact on life and esophageal cancer worry. Scale range is 0-10, 0 is min and 10 is max. Higher value represent worse outcome (such as higher concern about the condition of esophagus, negative impact on life and higher esophageal cancer worry).</description>
        <time_frame>12 month</time_frame>
        <population>943 subjects completed both baseline and follow up quality of life life survey</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Quality of Life Questionnaire Results: Change From Baseline to 12 Month</title>
          <description>Patient who completed both baseline and follow-up Quality of Life: Scores (0-10) of quality of life at baseline and 12 month follow-up were measured and changes were calculated ( 12 months minus baseline) in: concerns about the condition of esophagus, negative impact on life and esophageal cancer worry. Scale range is 0-10, 0 is min and 10 is max. Higher value represent worse outcome (such as higher concern about the condition of esophagus, negative impact on life and higher esophageal cancer worry).</description>
          <population>943 subjects completed both baseline and follow up quality of life life survey</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="943"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes:concern about the condition of esophagus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative impact on life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Esophageal cancer worry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event Incidence</title>
        <description>Adverse and Serious Adverse event with Definite device relationship</description>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Incidence</title>
          <description>Adverse and Serious Adverse event with Definite device relationship</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
Radiofrequency Ablation (HALO Ablation Systems): Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="5521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain, Nausea, vomitting, fullness, abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Dysphagia and/or Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Dysphagia/Upper GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Esophageal spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Esophagitis and/or Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Mucosal Tear / Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Stricture and/or dysphagia requiring dilatation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Upper GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="5521"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter interaction with existing sutures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Dysphagia and/or Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Esophageal spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Esophagitis and/or Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Mallory-weiss tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Mucosal Tear / Laceration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Mucosal trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Oxygen desaturation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Pain, Nausea, vomitting, fullness, abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Prior Stricture worsen by RFA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Sizing Balloon did not work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Stricture - no dilatation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Stricture and/or dysphagia requiring dilatation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Stricture requiring dilatation- History EMR or Stricture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5521"/>
              </event>
              <event>
                <sub_title>Upper GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5521"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Endoscopic clearance rate for Barrett's esophagus-Percentage of patients with no endoscopically visible Barrett's esophagus at 1 year follow-up: This endpoint is a visual and not reliable or accurate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nicholas Shaheen</name_or_title>
      <organization>University of north Carolina</organization>
      <phone>(919) 966-7047</phone>
      <email>nshaheen@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

